NutriBand (NTRB) Income from Continuing Operations (2016 - 2026)
NutriBand's (NTRB) quarterly Income from Continuing Operations came in at 968059.0 in Q1 2026, up 82.45% year-on-year from 530584.65 in Q1 2025, and up 75.0% quarter-over-quarter from 3872367.0 in Q4 2025.
NutriBand (NTRB) Income from Continuing Operations (2016 - 2026) Analysis & Trends
NutriBand has disclosed Income from Continuing Operations across 11 years of filings, most recently posting 968059.0 for Q1 2026.
- Income from Continuing Operations for Q1 2026 came in at 968059.0, up 82.45% year-over-year; the trailing twelve-month figure through Jan 2026 was 8229632.0 (up 21.49% YoY), and the FY2026 annual result was 8229632.0, up 21.49% from the prior year.
- Income from Continuing Operations came in at 968059.0 for Q1 2026 at NutriBand, up from 3872367.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 689989.0 in Q2 2022 to a low of 5516438.0 in Q1 2025.
- The 5-year median for Income from Continuing Operations is 1679325.0 (2023), against an average of 1908791.88.
- Across the five-year window, Income from Continuing Operations slumped 193.28% in 2025 and surged 82.45% in 2026, its largest moves.
- NutriBand's Income from Continuing Operations stood at 1075485.0 in 2022, then sank by 63.64% to 1759946.0 in 2023, then gained by 22.58% to 1362637.0 in 2024, then slumped by 184.18% to 3872367.0 in 2025, then soared by 75.0% to 968059.0 in 2026.
- The last three Income from Continuing Operations figures came in at 968059.0 (Q1 2026), 3872367.0 (Q4 2025), and 2000337.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - | - |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - | -14.46 Mn |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - | -3.40 Mn |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - | -56.48 Mn |
| 10 | NutriBand | 41.21 Mn | 36.63 Mn | 88,941.00 | -968,059.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jan 31, 2026 | -968,059.00 |
| Oct 31, 2025 | -3.87 Mn |
| Jul 31, 2025 | -2.00 Mn |
| Apr 30, 2025 | -1.39 Mn |
| Jan 31, 2025 | -5.52 Mn |
| Oct 31, 2024 | -1.36 Mn |
| Jul 31, 2024 | -1.71 Mn |
| Apr 30, 2024 | -1.90 Mn |
| Jan 31, 2024 | -1.88 Mn |
| Oct 31, 2023 | -1.76 Mn |
| Jul 31, 2023 | -829,173.00 |
| Apr 30, 2023 | -1.02 Mn |
| Jan 31, 2023 | -1.68 Mn |
| Oct 31, 2022 | -1.08 Mn |
| Jul 31, 2022 | -1.04 Mn |
| Apr 30, 2022 | -689,989.00 |
| Jan 31, 2022 | -3.77 Mn |
| Oct 31, 2021 | -1.57 Mn |
| Jul 31, 2021 | -519,923.00 |
| Apr 30, 2021 | -315,057.00 |